Ten things you should know about protein kinases: IUPHAR Review 14

被引:262
作者
Fabbro, Doriano [1 ]
Cowan-Jacob, Sandra W. [2 ]
Moebitz, Henrik [2 ]
机构
[1] PIQUR Therapeut, CH-4057 Basel, Switzerland
[2] Novartis Inst Biomed Res, Basel, Switzerland
基金
英国惠康基金;
关键词
CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; TYROSINE KINASE; SMALL-MOLECULE; BCR-ABL; ACQUIRED-RESISTANCE; SELECTIVE INHIBITOR; IRREVERSIBLE INHIBITORS; TARGETING KINASES; MAP KINASE;
D O I
10.1111/bph.13096
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the 10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.
引用
收藏
页码:2675 / 2700
页数:26
相关论文
共 296 条
[11]   Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma [J].
Ansari, Jawaher ;
Hussain, Syed A. ;
Ansari, Asif ;
Glaholm, John .
BIOLOGICS-TARGETS & THERAPY, 2013, 7 :39-46
[12]   Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia [J].
Apperley, Jane F. .
LANCET ONCOLOGY, 2007, 8 (11) :1018-1029
[13]   Activation of tyrosine kinases by mutation of the gatekeeper threonine [J].
Azam, Mohammad ;
Seeliger, Markus A. ;
Gray, Nathanael S. ;
Kuriyan, John ;
Daley, George Q. .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2008, 15 (10) :1109-1118
[14]   A screen to identify drug resistant variants to target-directed anti-cancer agents [J].
Mohammad Azam ;
Tal Raz ;
Valentina Nardi ;
Sarah L. Opitz ;
George Q. Daley .
Biological Procedures Online, 2003, 5 (1) :204-210
[15]   Dabrafenib: First Global Approval [J].
Ballantyne, Anita D. ;
Garnock-Jones, Karly P. .
DRUGS, 2013, 73 (12) :1367-1376
[16]   Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors [J].
Bantscheff, Marcus ;
Eberhard, Dirk ;
Abraham, Yann ;
Bastuck, Sonja ;
Boesche, Markus ;
Hobson, Scott ;
Mathieson, Toby ;
Perrin, Jessica ;
Raida, Manfred ;
Rau, Christina ;
Reader, Valerie ;
Sweetman, Gavain ;
Bauer, Andreas ;
Bouwmeester, Tewis ;
Hopf, Carsten ;
Kruse, Ulrich ;
Neubauer, Gitte ;
Ramsden, Nigel ;
Rick, Jens ;
Kuster, Bernhard ;
Drewes, Gerard .
NATURE BIOTECHNOLOGY, 2007, 25 (09) :1035-1044
[17]   Mutational analysis of the tyrosine kinome in colorectal cancers [J].
Bardelli, A ;
Parsons, DW ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Saha, S ;
Markowitz, S ;
Willson, JKV ;
Parmigiani, G ;
Kinzler, KW ;
Vogelstein, B ;
Velculescu, VE .
SCIENCE, 2003, 300 (5621) :949-949
[18]   Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].
Barker, AJ ;
Gibson, KH ;
Grundy, W ;
Godfrey, AA ;
Barlow, JJ ;
Healy, MP ;
Woodburn, JR ;
Ashton, SE ;
Curry, BJ ;
Scarlett, L ;
Henthorn, L ;
Richards, L .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914
[19]   Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors [J].
Barnett, SF ;
Defeo-Jones, D ;
Fu, S ;
Hancock, PJ ;
Haskell, KM ;
Jones, RE ;
Kahana, JA ;
Kral, AM ;
Leander, K ;
Lee, LL ;
Malinowski, J ;
McAvoy, EM ;
Nahas, DD ;
Robinson, RG ;
Huber, HE .
BIOCHEMICAL JOURNAL, 2005, 385 :399-408
[20]   The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity [J].
Barretina, Jordi ;
Caponigro, Giordano ;
Stransky, Nicolas ;
Venkatesan, Kavitha ;
Margolin, Adam A. ;
Kim, Sungjoon ;
Wilson, Christopher J. ;
Lehar, Joseph ;
Kryukov, Gregory V. ;
Sonkin, Dmitriy ;
Reddy, Anupama ;
Liu, Manway ;
Murray, Lauren ;
Berger, Michael F. ;
Monahan, John E. ;
Morais, Paula ;
Meltzer, Jodi ;
Korejwa, Adam ;
Jane-Valbuena, Judit ;
Mapa, Felipa A. ;
Thibault, Joseph ;
Bric-Furlong, Eva ;
Raman, Pichai ;
Shipway, Aaron ;
Engels, Ingo H. ;
Cheng, Jill ;
Yu, Guoying K. ;
Yu, Jianjun ;
Aspesi, Peter, Jr. ;
de Silva, Melanie ;
Jagtap, Kalpana ;
Jones, Michael D. ;
Wang, Li ;
Hatton, Charles ;
Palescandolo, Emanuele ;
Gupta, Supriya ;
Mahan, Scott ;
Sougnez, Carrie ;
Onofrio, Robert C. ;
Liefeld, Ted ;
MacConaill, Laura ;
Winckler, Wendy ;
Reich, Michael ;
Li, Nanxin ;
Mesirov, Jill P. ;
Gabriel, Stacey B. ;
Getz, Gad ;
Ardlie, Kristin ;
Chan, Vivien ;
Myer, Vic E. .
NATURE, 2012, 483 (7391) :603-607